Skip to content

Trial Summary

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).



ACTRN/NCT /ethics:


Scientific title:

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Sponsor / Cooperative group:

ICON / Regeneron

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhaseAll phases
Age Range18 years and older
Tumour Stream Cutaneous Squamous Cell Carcinoma
Cancer StageAll stages
Anticipated Start Date2019-06-04
Anticipated End Date2026-02-11

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Anne Taylor
Recruitment StatusRecruiting